From target identification and molecular design to patient stratification and clinical trial optimization, artificial intelligence (AI) is showing remarkable promise in accelerating drug discovery and ...

Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports long-term scale-up for its mRNA vaccine and therapeutic pipeline. The ...

Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular edema following retinal vein occlusion, with up to every eight-week dosing ...

Cancerguard, a multi-cancer early detection blood test.

In the first part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he provides a broad overview of the possible positive and negative ...

AbbVie and Genmab have received FDA approval for Epkinly as a treatment option for patients with relapsed or refractory follicular lymphoma. The decision adds a new targeted immunotherapy to the ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic collaboration with LTZ Therapeutics, advancing novel myeloid cell engagers in ...

Discover how AI-powered patient intelligence is ushering in a new era of pharma leadership defined by clarity, speed, and knowing the “why” behind every shift.

This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss the rising “clarity gap” that is currently putting pharma leaders under ...

David Edelman, Founder & CEO of Thrivable, provides an unflinching look at why today’s most relied-upon tools, including syndicated data, social listening, gut instinct, still leave leaders navigating ...

Learn how outdated or incomplete insights turn every decision into a high-stakes gamble that cost brands money, momentum, and internal alignment.

Understand how real-time patient intelligence transforms leadership conversations from speculation and opinion battles into confident, data-backed strategy.